Jason S Melo1, Solomon Aragie2, Ambahun Chernet2, Zerihun Tadesse2, Adane Dagnew2, Dagnachew Hailu2, Mahteme Haile3, Tàye Zeru3, Dionna M Wittberg1, Scott D Nash4, E Kelly Callahan4, Benjamin F Arnold1,5, Travis C Porco1,6,5, Thomas M Lietman1,6,5,7, Jeremy D Keenan1,5. 1. Francis I. Proctor Foundation, University of California San Francisco, San Francisco, California, USA. 2. The Carter Center Ethiopia, Addis Ababa, Ethiopia. 3. Amhara Public Health Institute, Bahir Dar, Ethiopia. 4. The Carter Center, Atlanta, Georgia, USA. 5. Department of Ophthalmology, University of California San Francisco, San Francisco, California, USA. 6. Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, California, USA. 7. Institute for Global Health, University of California San Francisco, San Francisco, California, USA.
Abstract
BACKGROUND: Current guidelines recommend community-wide mass azithromycin for trachoma, but a targeted treatment strategy could reduce the volume of antibiotics required. METHODS: In total, 48 Ethiopian communities were randomized to mass, targeted, or delayed azithromycin distributions. In the targeted arm, only children aged 6 months to 5 years with evidence of ocular chlamydia received azithromycin, distributed thrice over the following year. The primary outcome was ocular chlamydia at months 12 and 24, comparing the targeted and delayed arms (0-5 year-olds, superiority analysis) and the targeted and mass azithromycin arms (8-12 year-olds, noninferiority analysis, 10% noninferiority margin). RESULTS: At baseline, the mean prevalence of ocular chlamydia in the 3 arms ranged from 7% to 9% among 0-5 year-olds and from 3% to 9% among 8-12 year-olds. Averaged across months 12-24, the mean prevalence of ocular chlamydia among 0-5 year-olds was 16.7% (95% confidence interval [CI]: 9.0%-24.4%) in the targeted arm and 22.3% (95% CI: 11.1%-33.6%) in the delayed arm (P = .61). The final mean prevalence of ocular chlamydia among 8-12 year-olds was 13.5% (95% CI: 7.9%-19.1%) in the targeted arm and 5.5% (95% CI: 0.3%-10.7%) in the mass treatment arm (adjusted risk difference 8.5 percentage points [pp] higher in the targeted arm, 95% CI: 0.9 pp-16.1 pp higher). CONCLUSIONS: Antibiotic treatments targeted to infected preschool children did not result in significantly less ocular chlamydia infections compared with untreated communities and did not meet noninferiority criteria relative to mass azithromycin distributions. Targeted approaches may require treatment of a broader segment of the population in areas with hyperendemic trachoma.
BACKGROUND: Current guidelines recommend community-wide mass azithromycin for trachoma, but a targeted treatment strategy could reduce the volume of antibiotics required. METHODS: In total, 48 Ethiopian communities were randomized to mass, targeted, or delayed azithromycin distributions. In the targeted arm, only children aged 6 months to 5 years with evidence of ocular chlamydia received azithromycin, distributed thrice over the following year. The primary outcome was ocular chlamydia at months 12 and 24, comparing the targeted and delayed arms (0-5 year-olds, superiority analysis) and the targeted and mass azithromycin arms (8-12 year-olds, noninferiority analysis, 10% noninferiority margin). RESULTS: At baseline, the mean prevalence of ocular chlamydia in the 3 arms ranged from 7% to 9% among 0-5 year-olds and from 3% to 9% among 8-12 year-olds. Averaged across months 12-24, the mean prevalence of ocular chlamydia among 0-5 year-olds was 16.7% (95% confidence interval [CI]: 9.0%-24.4%) in the targeted arm and 22.3% (95% CI: 11.1%-33.6%) in the delayed arm (P = .61). The final mean prevalence of ocular chlamydia among 8-12 year-olds was 13.5% (95% CI: 7.9%-19.1%) in the targeted arm and 5.5% (95% CI: 0.3%-10.7%) in the mass treatment arm (adjusted risk difference 8.5 percentage points [pp] higher in the targeted arm, 95% CI: 0.9 pp-16.1 pp higher). CONCLUSIONS: Antibiotic treatments targeted to infected preschool children did not result in significantly less ocular chlamydia infections compared with untreated communities and did not meet noninferiority criteria relative to mass azithromycin distributions. Targeted approaches may require treatment of a broader segment of the population in areas with hyperendemic trachoma.
Authors: Teshome Gebre; Berhan Ayele; Mulat Zerihun; Asrat Genet; Nicole E Stoller; Zhaoxia Zhou; Jenafir I House; Sun N Yu; Kathryn J Ray; Paul M Emerson; Jeremy D Keenan; Travis C Porco; Thomas M Lietman; Bruce D Gaynor Journal: Lancet Date: 2011-12-20 Impact factor: 79.321
Authors: Anthony W Solomon; Martin J Holland; Neal D E Alexander; Patrick A Massae; Aura Aguirre; Angels Natividad-Sancho; Sandra Molina; Salesia Safari; John F Shao; Paul Courtright; Rosanna W Peeling; Sheila K West; Robin L Bailey; Allen Foster; David C W Mabey Journal: N Engl J Med Date: 2004-11-04 Impact factor: 91.245
Authors: J-F Schémann; C Guinot; L Traore; G Zefack; M Dembele; I Diallo; A Traore; P Vinard; D Malvy Journal: Acta Trop Date: 2006-12-16 Impact factor: 3.112
Authors: Jade Benjamin-Chung; Benjamin F Arnold; David Berger; Stephen P Luby; Edward Miguel; John M Colford; Alan E Hubbard Journal: Int J Epidemiol Date: 2018-02-01 Impact factor: 7.196
Authors: Emily S West; Beatriz Munoz; Harran Mkocha; Martin J Holland; Aura Aguirre; Anthony W Solomon; Robin Bailey; Allen Foster; David Mabey; Sheila K West Journal: Invest Ophthalmol Vis Sci Date: 2005-01 Impact factor: 4.799
Authors: Matthew J Burton; Martin J Holland; Pateh Makalo; Esther A N Aryee; Neal D E Alexander; Ansumana Sillah; Hannah Faal; Sheila K West; Allen Foster; Gordon J Johnson; David C W Mabey; Robin L Bailey Journal: Lancet Date: 2005 Apr 9-15 Impact factor: 79.321
Authors: Aisha E P Stewart; Mulat Zerihun; Demelash Gessese; Berhanu Melak; Eshetu Sata; Andrew W Nute; Tigist Astale; Tekola Endeshaw; Tesfaye Teferi; Zerihun Tadesse; Elizabeth Kelly Callahan; Melsew Chanyalew; Birhan Gaudie; Paul M Emerson; Jonathan D King; Scott D Nash Journal: Am J Trop Med Hyg Date: 2019-12 Impact factor: 2.345
Authors: Anthony W Solomon; Matthew J Burton; Emily W Gower; Emma M Harding-Esch; Catherine E Oldenburg; Hugh R Taylor; Lamine Traoré Journal: Nat Rev Dis Primers Date: 2022-05-26 Impact factor: 52.329
Authors: Ahmed M Arzika; Dallas Mindo-Panusis; Amza Abdou; Boubacar Kadri; Beido Nassirou; Ramatou Maliki; Amer F Alsoudi; Tianyi Zhang; Sun Y Cotter; Elodie Lebas; Kieran S O'Brien; E Kelly Callahan; Robin L Bailey; Sheila K West; E Brook Goodhew; Diana L Martin; Benjamin F Arnold; Travis C Porco; Thomas M Lietman; Jeremy D Keenan Journal: JAMA Netw Open Date: 2022-08-01